Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement
December 05, 2024 09:00 ET
|
Qualigen Therapeutics, Inc.
Carlsbad, CA, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics (NASDAQ: QLGN) (the “Company” or “Qualigen”) today announced that the Company received formal notice from The Nasdaq Stock...
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
November 25, 2024 17:00 ET
|
Univest Securities, LLC
New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York,...
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares
November 19, 2024 09:00 ET
|
Qualigen Therapeutics, Inc.
Carlsbad, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), Qualigen Therapeutics, Inc., is a life science company focused on developing...
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024
November 01, 2024 09:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued...
Qualigen Therapeutics, Inc. Announces management changes.
September 26, 2024 17:10 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors...
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
September 20, 2024 09:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasdaq...
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering
September 06, 2024 16:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the closing of its previously announced public offering of 14,724,058...
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering
September 05, 2024 09:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stock,...
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
May 30, 2024 16:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), announced today that on May 23, 2024, it received written notice (the...
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
April 09, 2024 08:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience...